Holen Sie sich die Stockscreener-App
57.52
5.46%
2.98
Vorhandelsmarkt:
57.01
-0.51
-0.89%
Schlusskurs vom Vortag:
$54.54
Offen:
$55
24-Stunden-Volumen:
1.15M
Relative Volume:
2.26
Marktkapitalisierung:
$3.54B
Einnahmen:
$112.53M
Nettoeinkommen (Verlust:
$-258.91M
KGV:
-13.28
EPS:
-4.33
Netto-Cashflow:
$-124.42M
1W Leistung:
+6.64%
1M Leistung:
+2.49%
6M Leistung:
+16.04%
1J Leistung:
+40.16%
1-Tages-Spanne:
$55.00
$57.58
1-Wochen-Bereich:
$52.70
$57.58
52-Wochen-Spanne:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
57.52 | 3.54B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Earnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growth - Investing.com India
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price - Simply Wall St
JPMorgan Chase & Co. Sells 58,554 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Long Term Trading Analysis for (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $68.09 Average Target Price from Analysts - Defense World
Head to Head Review: ABVC BioPharma (NASDAQ:ABVC) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm gets FDA approval for Imcivree for toddlers - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Harbor Capital Advisors Inc. Sells 11,116 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ: RYTM) Reports Strong Growth in Revenue and Clinical Development Initiatives - Defense World
Rhythm Pharmaceuticals price target raised to $60 from $58 at BofA - MSN
Rhythm Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
Rhythm Pharmaceuticals Reports Growth and Expands Pipeline - TipRanks
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones - The Manila Times
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product - The Bakersfield Californian
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire
Rhythm Pharmaceuticals Delivers Record $130M Revenue in 2024, Q4 Sales Surge 26% - StockTitan
Principal Financial Group Inc. Has $1.71 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Principal Financial Group Inc. Buys 23,054 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Jefferies Financial Group - Defense World
Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential - Yahoo Finance
Jefferies Financial Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Where are the Opportunities in (RYTM) - Stock Traders Daily
Stifel Financial Corp Has $1.04 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Market Outperform Rating from JMP Securities - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Buy Rating from HC Wainwright - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given "Market Outperform" Rating at JMP Securities - MarketBeat
Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years - Yahoo Finance
Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FDA nod for Rhythm Pharma’s Imcivree - The Pharma Letter
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Price Target at $64.67 - Defense World
Franklin Resources Inc. Purchases 26,739 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Barclays PLC Buys 47,166 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharma Modifies Trials of Genetic Obesity Medicine; Shares Drop - Marketscreener.com
Oppenheimer Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - MSN
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children - MarketWatch
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential - Benzinga
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® - GlobeNewswire
Rhythm Pharma's IMCIVREE Wins FDA Approval for Rare Obesity Treatment in Young Children - StockTitan
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Oppenheimer - MarketBeat
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals - Benzinga
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $64.67 - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Wellington Management Group LLP - MarketBeat
Ionq Inc (IONQ-N) QuotePress Release - The Globe and Mail
(RYTM) Trading Signals - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by State Street Corp - MarketBeat
Fmr LLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
BNP Paribas Financial Markets Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Frazier Life Sciences Management L.P. Acquires 45,648 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
National Bank of Canada FI Has $17.89 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):